Roche makes $230 million bet on hepatitis drug developer Anadys
Roche is making a $230 million bet on hepatitis C drug developer Anadys Pharmaceuticals, a company the big Swiss drug maker agreed to buy for a whopper of a premium.
Swiss drug developer Roche boosted its hostile tender offer for biotechnology pioneer Genentech Inc. to US$93 per share Friday, raising the total offer value to $45.7 billion, after its initial offer failed to pick up much support from shareholders.